<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Download Champions' latest AACR 2024 Poster

Unveiling the Correlation between gemtuzumab-ozogamicin Efficacy and CD33+ Expression in AML Primary Samples Using the Novel AML VitroScreen

 

Mylotarg Poster 2064 AACR_28Mar2024.pdf

 

 

Acute myeloid leukemia (AML) is an aggressive, relapsing disorder with limited treatment options due to the lack of AML-specific antigens. CD33, found on 80-90% of AML cells, is targeted by Mylotarg, the only FDA-approved ADC for AML. However, the absence of suitable models to capture AML's complexity hinders therapeutic progress. Champions' AML VitroScreen platform addresses this by testing therapeutic candidates in primary AML samples.

  • A proprietary assay for testing therapeutic candidates in primary AML samples, analyzing viability, proliferation, and clonal composition across subtypes.

  • The AML VitroScreen platform classifies models as responders, low responders, or resistant, offering insights into treatment efficacy.

  • Flow cytometry shows a strong correlation between Mylotarg sensitivity and CD33 expression, confirming CD33 as a key marker for identifying suitable patients.





 

Download the Poster